Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:35:40.168Z.
Calculation as of: 2026-10-06T13:35:40.168Z.
Quote observation: 2026-10-06T13:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6c02d81e284155bdcda1783dec911e9c0a395e203238f61c1cccf60d236910ce
PE RATIO
N/A
Market Cap
$8.75B
PE Ratio
N/A
TTM Avg
41.90
3Y Avg
41.90
5Y Avg
41.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.98B | N/A | N/A | N/A | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $9.13B | N/A | N/A | N/A | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.75B | N/A | 41.90 | 41.90 | 41.90 |
| Bruker Corporation (BRKRP)vs › | $9.57B | N/A | 552.62 | 552.62 | 552.62 |
| Caris Life Sciences, Inc. (CAI)vs › | $9.08B | 89.72 | 73.85 | 73.85 | 73.85 |
| Insulet Corp. (PODD)vs › | $9.39B | 25.35 | 58.80 | 65.23 | 3594.22 |
| Oscar Health, Inc. (OSCR)vs › | $8.43B | 23.21 | 22.16 | 45.57 | 45.57 |
| Henry Schein, Inc. (HSIC)vs › | $9.76B | 24.98 | 23.93 | 23.91 | 21.89 |
| Bruker Corporation (BRKR)vs › | $10.00B | N/A | 54.08 | 39.03 | 41.91 |
| Krystal Biotech, Inc. (KRYS)vs › | $9.88B | 42.00 | 40.13 | 207.84 | 207.84 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$174.60
Forward EPS (Est.)
$-2.70
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
